Accessibility Tools

Skip to main content

John C. Luce

Mr. Luce is a Clarkson-Cornell-Exxon Research and Engineering trained chemical engineer and George Washington University Law School trained intellectual property attorney who specializes in procuring, enforcing, and exploiting domestic and foreign patent rights.

Background

Undergraduate Education

  • Clarkson University, Potsdam, New York
    B.S., Chemical Engineering
    Presidential Scholar; Omega Chi Epsilon, National Chemical Engineering Honorary Society

Postgraduate Education

  • Cornell University, Ithaca, New York
    Master of Engineering (Chemical)
    Olin Corporation Fellowship
  • The George Washington University, National Law Center, Washington, DC
    J.D.
    Honors, Legal Research and Writing; Moot Court Board; American Intellectual Property Law Association
    16th Annual Giles S. Rich Moot Court Competition – National semi-finalist

Technical Experience

  • Exxon Research and Engineering Company,
    Petroleum and Synthetic Fuels Department, Florham Park, New Jersey
    Senior Engineer

Admitted to Bar for

  • Registered to practice as a patent attorney before the Patent and Trademark Office
  • Commonwealth of Pennsylvania
  • United States Court of Appeals for the Federal Circuit
  • District of Columbia
  • Supreme Court of the United States

Memberships

  • American Institute of Chemical Engineers (AIChE)
    Catalysis & Reaction Engineering and Fuels & Petrochemicals Divisions
  • American Intellectual Property Law Association (AIPLA)
    Chemical Practice and Patent Law Committees
  • Federal Circuit Bar Association
  • Society of Petroleum Engineers

Publications

  • Author, “Summary of Oral Argument in Hilton Davis Chemical Co. v. Warner-Jenkinson Co. Inc.,” NGB Corporation Intellectual Property Report, November 1996
  • Co-author, “Responding to Office Actions,” Cushman, Darby & Cushman 13th Annual Intellectual Property Seminar Handbook, 1990
  • Co-author, “Intellectual Property Rights in Inventions Developed with Federal Funds,” The Food and Drug Law Institute, November 1989